NSE · SMSPHARMA
SMS Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹207 Cr with net profit ₹21 Cr — a 10.21% net margin, versus 11.39% the period before.
Shareholding
As of 2026-09-30
- Promoter68.07%
- Public30.56%
- FII1.18%
- DII0.2%
34,904 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.83× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #5 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,40,249 Cr | 80.64 | 14.37 | 15.32% | 26.05% |
| Acutaas Chemicals Limited | ₹27,417 Cr | 70.99 | 16.58 | 21.54% | 26.42% |
| Neuland Laboratories Ltd. | ₹24,447 Cr | 49.11 | 13.06 | 19.42% | 20.99% |
| Jubilant Pharmova Ltd. | ₹14,925 Cr | 38.46 | 2.11 | 5.62% | 4.11% |
| SMS Pharmaceuticals Ltd.(this company) | ₹3,913 Cr | 38.23 | 4.97 | 12.98% | 11.41% |
| Aarti Drugs Ltd. | ₹3,462 Cr | 17.97 | 2.24 | 12.58% | 7.14% |
| Hikal Limited | ₹2,404 Cr | 56.67 | 2 | 3.03% | -1.96% |
| Beta Drugs Limited | ₹2,200 Cr | 42.24 | 5.03 | 11.86% | 11.69% |
| NGL Fine Chem Limited | ₹1,621 Cr | 28.35 | 4.92 | 14.62% | 10.67% |
| Fermenta Biotech Ltd. | ₹1,316 Cr | 24.03 | 3.23 | 17.67% | 11.68% |
AI analysis
AI-generated · google/gemini-2.5-flashSMS Pharmaceuticals Ltd. is listed on the Indian markets. The company reported revenue of Rs 788.97 Cr and a profit margin of 11.5%. Its market capitalization stands at Rs 3600 Cr, with earnings per share (EPS) of 10.89. The stock's 52-week high is Rs 447.8 and its 52-week low is Rs 207.99.
Positives
- +Revenue grew by 10.4% to Rs 788.97 Cr in Mar 2025.
- +The company maintains a profit margin of 11.5%.
- +Promoter holding is substantial at 68.0658% as of June 30, 2026.
- +Debt-to-equity ratio is 0.5.
- +Dividend yield is 10%, which is relatively high.
Negatives
- −The percentage of promoter shares pledged is 17.99% as of June 30, 2026.
- −DII holding is low at 2.8314% as of June 30, 2026.
- −FII holding is low at 0.6493% as of June 30, 2026.
- −Promoter pledge percentage has increased from 3.55% in Dec 2016 to 17.99% in Jun 2026.
- −No quarterly results have been disclosed since Mar 2026.
Financial Performance
SMS Pharmaceuticals Ltd. reported annual revenue of Rs 788.97 Cr for Mar 2025, reflecting a growth of 10.4%. Net profit for Mar 2025 was Rs 69.1356 Cr. Quarterly revenue for Mar 2026 was Rs 237.95 Cr, generating a net profit of Rs 32.71 Cr. The December 2025 quarter saw revenue of Rs 210.45 Cr and a net profit of Rs 23.47 Cr.
Profitability & Returns
The company's profit margin was 11.5%. Return on equity (ROE) was 12.98%, and return on capital employed (ROCE) stood at 12.1399%. Earnings per share (EPS) for Mar 2025 was 8.16, with the most recent EPS reported as 10.89.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.5. Book value per share is Rs 83.91. While specific assets and liabilities are not provided, the debt-to-equity ratio indicates the company's reliance on debt financing relative to equity.
Ownership & Pledges
As of June 30, 2026, promoter holding in SMS Pharmaceuticals Ltd. was 68.0658%. Public shareholding was 28.4535%, with DIIs holding 2.8314% and FIIs holding 0.6493%. A total of 17.99% of promoter shares were pledged. The number of shareholders as of June 30, 2026, was 31489.
Regulatory & Surveillance
No specific information regarding regulatory actions or surveillance measures against SMS Pharmaceuticals Ltd. was provided in the available data.
Data as of — price: 2026-10-27 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.